TOTAL: $1,662.8
Company (Symbol)# |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount Raised ($M)* |
Investors; Placement Agents; Details (Date)@ |
Aastrom Biosciences Inc. (ASTM) |
Private placement of units |
2.26U |
$6 |
Aastrom raised $6M through the sale to a single investor of 2.26M units, each of which consists of one share of common stock and a three-year warrant to purchase one-half of one share of common stock at an exercise price of $3.70; full exercise of the warrants would raise an additional $4.2M (3/2) |
Alexion Pharmaceuticals Inc. (ALXN) |
Private placement of convertible subordinated notes |
-- |
$120 |
Alexion raised $120M through the placement of 5.75% convertible subordinated notes due 3/15/07; notes are convertible to Alexion common stock at $106.43 per share (3/3) |
AltaRex Corp. (Canada; TSE:AXO) |
Exercise of stock options |
1.96S |
C$0.98 (US$0.67) |
National Bank Financial Inc. and HSBC James Capel Canada Inc. exercised all their compensation options to acquire 1.96M common shares of AltaRex; the options were issued mid-1999 as partial compensation for services provided to the company in a public offering; net proceeds to the company total $0.98M (US$0.67M) (3/9) |
Antex Biologics Inc. (OTC BB: ANTX) |
Private placement of common stock and warrants |
23.2U |
$15.3 |
Antex netted $15.1M in a self-managed placement of common stock and warrants; the company sold 18.7M "A" units and 4.5M "B" units, in each case at a price of $0.66 per unit; each "A" unit consists of one share of common stock and one Class A warrant, which has a five-year term and is exercisable immediately for purchase of one share of common stock at $1.50 per share; each "B" unit consists of 1/100 share of Series A convertible preferred stock and one Class B warrant; beginning one year following the issue date, each 1/100 share of preferred stock is convertible into one share of common stock; Class B warrants are identical to Class A warrants except they do not become exercisable until until one year after issuance (3/16) |
Aquila Biopharmaceuticals Inc. (AQLA) |
Private placement of common stock |
0.5S |
$3.03 |
Aquila raised $3.03M in a self-directed private placement of 0.5M shares of common stock with the State of Wisconsin Investment Board (3/23) |
AutoImmune Inc. (AIMM) < |
Sale of patent rights |
-- |
$7 |
A subsidiary of Elan Corp. plc (Ireland; NYSE: ELN) purchased all of AutoImmune's rights to a group of patent applications related to treatment of Alzheimer's disease; AutoImmune will receive up to $7M in cash through a combination of up-front fees and contingent payments over three years; when those payments are made, the buyer will receive warrants to purchase up to 0.75M shares of AutoImmune stock at the market price when the warrants were issued (3/21) |
Avax Technologies Inc. (AVXT) |
Private placement of common stock and warrants |
2.26S and warrants for 0.23S |
$25.1 |
Avax sold 2.26M shares of common stock at $11.125 per share and warrants to purchase an additional 0.23M shares of common stock at $12.79< per share or 115% of the offering price; Gruntal & Co. LLC acted as placement agent (3/13) |
Axonyx Inc. (OTC BB: AXYX) |
Private placement of units |
188U |
$4.7 |
Axonyx sold 188 units at $25,000 each to raise $4.7M; each unit consists of 4,000 shares of restricted common stock and 2,000 five-year warrants exercisable at $11 (3/1) |
BioChem Pharma Inc. (BCHE) |
Divesture of division |
-- |
$54 |
BioChem sold its diagnostics division, BioChem ImmunoSystems Inc. to a minority shareholder and management group; BioChem received a $54M debenture to be paid out of future cash flows (3/15) |
Biomira Inc. (BIOM) |
Draw down of equity line of financing |
$29 |
Biomira issued $29M worth of new stock; terms of 2/99 financing agreement allowed for tranches of $10M, for up to $100M; the underwriter agreed to let Biomira take advantage of a strong stock price to drawn down a larger amount (3/17) |
|
Cel-Sci Corp. (AMEX:CVM) |
Private placement of common stock |
$7.7 |
Cel-Sci sold $7M worth of stock to two institutional investors (3/16), along with $0.7M to a director (3/24) |
|
Celsion Corp. (OTC BB: CELN) |
Exercise of warrants |
5.28S |
$5 |
Holders of Celsion's Series 700 and 800 warrants exercised warrants in response to Celsion's call for redemption; Series 700 warrant holders bought 2.63M shares at $1 each and Series 800 warrant holders bought 2.65M shares at $0.90 each (3/15) |
CV Therapeutics Inc. (CVTX) |
Private placement of convertible subordinated notes |
-- |
$196.25 |
CV Therapeutics sold $175M worth of 4.75% convertible subordinated notes due 3/7/07; the notes are convertible into shares of CV common stock at $63.84 per share, subject to adjustment in certain circumstances (3/2); initial purchasers exercised overallotment option for $21.25M worth of additional notes (3/16) |
Cytoclonal Pharmaceutics Inc. (CYPH) |
Exercise of warrants |
1.94S |
$12.6 |
About 97% of Class C warrants were redeemed, with holders exercising each warrant to buy one share of common stock and one Class D warrant for a total of $6.50; each Class D warrant is exercisable for one share of common stock at $8.75; the Class D warrants expire 11/2/00 (3/13) |
Demegen Inc. (OTC BB: DBOT) |
Private placement of restricted shares of common stock and warrants |
5.4S and warrants for 5.4S |
$2.7 |
Demegen sold 5.4M restricted shares of common stock and warrants to purchase 5.4M common shares (3/17) |
DiagnoCure Inc. (TSE:CUR) |
Private placement of special warrants |
1.25W |
$5 |
DiagnoCure sold 1.25M special warrants at $4 each for a total of $5M; each special warrant is exchangeable for one common share without additional payment (3/16) |
Discovery Laboratories Inc. (DSCO) |
Private placement of common stock and warrants |
2.8S and 0.57W |
$18.5 |
Discovery raised approximately $18.5M through a private placement of 2.8M shares and 0.57M warrants; investors include PIMCO Equity Advisors, The Lincoln Fund, Royal Bank of Canada, The Keys Foundation, Albert Fried and Co., and Credito Privato Commerciale; Paramount Capital acted as placement agent (3/20) |
Flamel Technologies |
Private placement of units (France; FLMLY) |
3.2U |
$12.8 |
Flamel sold 3.2M units at $4 each to raise $12.8M; each unit consists of one ordinary share, 0.56 of a Class A warrant and 0.60 of a combination of Class B or C warrants; altogether, 3.21M shares are to be issued, along with warrants for a total of 3.73M ordinary shares; the warrants have a five-year term; investors are Biotechnology Value Fund, Alta BioPharma Partners and Chase Capital Partners (3/23) |
GelTex Pharmaceuticals Inc. (GELX) |
Private placement of common stock |
1.75S |
$35 |
GelTex raised $35M through the sale of 1.75M shares at $20 per share to institutional investors; the company also entered an agreement with Acqua Wellington North American Equities Fund Ltd. for a financing facility covering the sale of up to >1.75M shares of common stock over the next 12 months at GelTex's discretion at a small discount to market price; transactions stemmed from a shelf registration covering up to 3.5M shares (3/13) |
Geron Corp. (GERN) |
Private placement of common stock and warrants |
-- |
$9 |
Geron sold $9M in common stock and warrants to an individual investor; the common stock and stock underlying the warrants are subject to a two-year prohibition on sale; the transaction was structured in two tranches, the first of which consisted of common stock priced at market and warrants priced at a premium to market; the second tranche, 30% of the total, was priced at a discount to market (3/10) |
Helix Biopharma (Canada: TSE:HBP) |
Private placement of special warrants |
3W |
C$12.75 (US$8.7) |
Pacific International Securities and Roche Securities Ltd. paid C$4.25 (US$2.90) each for 3M warrants, convertible into 3M common shares at C$6.66 (US$4.53) for one year and warrants to buy 1.5M shares at C$10 (US$6.80) for two years (3/20) |
Human Genome Sciences Inc. |
Private placement of convertible subordinated notes |
-- |
$300 |
HGS raised $300M through the private placement of $300M worth of 3.75% convertible subordinated notes due 2007; notes are convertible into HGS common stock at $219 per share (3/10) |
Ilex Oncology Inc. (ILXO) |
Private placement of common stock |
3S |
$135 |
Ilex sold 3M shares of common stock at $45 per share to institutional and other investors for a total of $135M ($127M net); a selling stockholder sold an additional 1.26M shares; Prudential Vector Healthcare Group served as placement agent (3/7) |
Immune Network Research Ltd. (Canada; CDNX:IMM) |
Private placement of special warrants |
15.45W |
C$8.5 US$5.83 |
Immune Network sold 15.45M special warrants at C$0.55 (US$0.38) per special warrant in a brokered private placement with Groome Capital.com Inc.; each is exercisable into one unit at no additional cost, each unit consisting of one common share and a half-share purchase warrant; each whole-share purchase warrant entitles the holder to purchase one additional common share at C$1.40 (US$0.96) for 18 months (3/9) |
Inflazyme Pharmaceuticals Ltd. (Canada; CDNX:IZP) |
Exercise of warrants |
3.26S and 0.37W |
$7.57 |
Goldman Sachs Group Inc. and Biotechnology Investments Ltd. exercised all of their Series A common share purchase warrants, receiving a total of 3.2M shares for total proceeds of $7.11M ($2.18 per share); in addition, National Bank Financial Inc. exercised 0.37M agent warrants (issued in connection with a 1999 financing) for total proceeds of $0.46M (3/7) |
Isis Pharmaceuticals Inc. (ISIP) |
Offering of common stock under a shelf registration |
1S |
$27.25 |
Isis raised $27.25M through the sale of 1M shares at $27.25 per share; financing is part of an ongoing relationship with principal investor Acqua Wellington North American Equities Fund Ltd., and was underwritten by Ridgeway Investments Ltd.; the offering was made pursuant to shelf registration for up to 4M shares (3/8) |
KS Biomedix plc (UK; LSE: KSB) |
Placement of ordinary shares |
2.27S |
#15.82 US$24.97 |
KS placed 2.27M ordinary shares at 698 pence (US$11.02) to raise #15.82M (US$24.97M); the placement was fully underwritten by WestLB Panmure Ltd. (3/1) |
Micrologix Biotech Inc. (Canada; TSE:MBI) |
Private placement of special warrants |
4W |
$40 |
Micrologix raised $40M through a private placement of 4M special warrants at $10 each via a syndicate of underwriters co-led by TD Securities Inc. and Yorkton Securities Inc., and including RBC Dominion Securities Inc., Goepil McDermid Inc. and Canaccord Capital Corp.; each warrant will entitle the holder to acquire, at no additional cost, one common share of Micrologix (3/20) |
NeoTherapeutics Inc. (NEOT) |
Private placement of common stock |
0.52S |
$8 |
NeoTherapeutics sold 0.52M shares of common stock at $15.375 per share, a 12% premium; investors also receive five-year warrants to purchase 0.1M shares of common stock at $21 per share (3/6) |
Novavax Inc.(AMEX: NOX) |
Exercise of stock options and warrants |
0.85S |
$3.6 |
Novavax received $3.6M when Anaconda Opportunity Fund LP exercised its warrant to purchase 0.66M shares of common stock for $3.6M; in addition, Anaconda was issued 0.19M shares in a cash-less exercise of additional warrants to purchase Novavax stock (3/15) |
Nymox Pharmaceutical Corp. (NYMX) |
Private placement of shares and warrants |
0.67S and 0.07W |
$4 |
Nymox raised $4M through a private placement of 0.67M shares and 0.07M warrants; investment was placed by Ladenburg Thalmann & Co. (3/14) |
Ophidian Pharmaceuticals Inc. (OPHD) |
Sale of patents and patent applications |
-- |
$1.3 |
Ophidian sold five patents and patent applications to an undisclosed buyer for $1.3M (3/28) |
Organogenesis Inc. (AMEX: ORG) |
Private placement of shares |
0.3S |
$5.3 |
Organogenesis, which raised $10.8M in 2/00, directly placed an additional 0.3M shares at $17.625 per share, raising $5.3M (3/9) |
Ortec International Inc. (ORTC) |
Private placement of common stock |
0.07S |
$1 |
New Medical Technologies (Switzerland) bought 0.067M shares at $15 each, for a total of $1M; Robert Mitani Capital LLC, an affiliate of Aqua Partners, acted as placement agent (3/13) |
Oxford GlycoSciences plc (UK; LSE:OGS) |
Placement of common shares to existing stockholders |
2.1S |
#35.3 (US$55.6) |
OGS netted #33.2M (US$52.3) from a placement that allowed existing share holders to buy 1 share at 1,700 pence (US$26.78; a 6.72% discount to the 2/24 price) for every 18 shares owned; the placement was underwritten by Lehman Brothers; Lehman and Cazenove & Co. were brokers to the issue (3/20) |
Oxis International Inc. (OXIS) |
Private placement of units |
1U |
$4.8 |
Oxis raised approximately $4.8M in the first tranche of a units financing; each unit is priced at $4.75 and consists of one share of common stock and warrants to purchase two shares, one of which may be purchased at $5.94, the other share covered by the warrants may be purchased at $7.13 (3/7) |
Pharmacopeia Inc. (PCOP) |
Private placement of common stock |
1.86S |
$117 |
Pharmacopeia raised $117M through the sale of 1.86M shares of common stock at $63 per share to institutional investors (3/8) |
Pharmacyclics Inc. (PCYC) |
Private placement of common stock |
0.82S |
$60 |
Pharmacyclics raised $60M through the sale of 0.82M shares of common stock at $73.75 per share to selected institutional investors (3/2) |
Protein Polymer Technologies Inc. (PPTI) |
Exercise of warrants |
4.2S |
$2.1 |
Protein Polymer received $2.1M through conversion of warrants to common stock at $0.50 per share (3/7) |
Repligen Corp. (RGEN) |
Private placement of common stock |
2.6S |
$22.4 |
Repligen raised $22.4M through the sale of 2.6M shares at $8.625 per share; Paramount Capital Inc. acted as financial advisor (3/7) |
SafeScience Inc. (SAFS) |
Two private placements of common stock and warrants |
0.68S and warrants for .87S |
$9 |
SafeScience conducted two separate private placements of equity; in the one transaction, the company raised $5M through the sale of 0.35M shares at $14.45 per share; shares included a warrant to purchase 0.11M shares at $15.98 per share; the investors, led by Cavallo Capital Corp., will buy up to $9M worth of additional stock, subject to certain conditions; in the other transaction, SafeScience raised $3M in a placement of 0.33M shares at $12 per share; shares included a warrant to purchase an additional 0.76M shares at $15.98 per share; Gerard Klauer Mattison & Co. Inc. and George K. Baum & Co. acted as placement agents for the transactions (3/31) |
Sangui BioTech International Inc. (Germany; OTC BB:SGBI) |
Regulation S sale of common stock |
8S |
$7.71 |
Sangui issued 8M shares at $0.96 per share to longterm financial partner Euro-American GmbH (Germany); the shares will be issued under Regulation S with a restriction term of 24 months (3/31) |
Select Therapeutics Inc. (OTC BB: SLPU) |
Private placement of equity |
ND |
$9.5 |
Select Therapeutics raised $9.5M; Clayton Dunning & Co. Inc. acted as placement agent (3/31) |
SignalGene (TSE:SGI) |
Private placement |
7.16S |
C$3.7 (US$2.5) |
In conjunction with the acquisition of GeneScape Inc., SignalGene raised C$2.7M (US$1.85M) in a private placement with two existing GeneScape shareholders: the Business Development Bank of Canada and Royal Bank Venture Inc.; Societe Innovatech du Grand Montreal also bought $1M (US$0.68M) worth of stock (4/14) |
Synsorb Biotech Inc. (Canada; SYBB) |
Sale of subsidiary |
-- |
ND |
Synsorb sold INH Technologies Inc., a subsidiary, to MDS Inc. (Canada; TSE:MDS.A) for an undisclosed cash payment, plus future milestones and royalties (3/7) |
Targeted Genetics Corp. (TGEN) |
Private placement of common stock |
2.16S |
$30.3 |
Targeted raised $30.3M through the sale of 2.16M shares of common stock at $14 per share; investors are Franklin Templeton Group, Invesco Funds, Lone Pine Capital LLC, International Biotechnology Trust, and Deerfield Management Co.; Chase H&Q served as placement agent (3/1) |
Theratechnologies (TSE:TH) |
Exercise of warrants |
0.5S |
C$3.05 US$2.1 |
The Societe generale de financement du Quebec exercised 0.5M warrants at C$6.10 (US$4.15), for a total of C$3.05M; warrants stem from 6/99 financing (3/20) |
Vasogen Inc. (Canada; TSE: VAS) |
Private placement of special warrants |
1.725W |
C$15.5 US$10.7 |
Vasogen raised C15.5M (US$10.7M) through a private placement of 1.725M special warrants at C$9 (US$6.21); each warrant is convertible into one share of Vasogen for no additional consideration (3/1) |
Vertex Pharmaceuticals Inc. (VRTX) |
Private placement of convertible subordinated notes |
-- |
$175 |
Vertex sold $175M worth of 5% notes, due 3/07; notes are convertible into common stock at $80.64 per share (3/9) |
Vion Pharmaceuticals Inc. (VION) |
Exercise of warrants |
1.07S and 1.07W |
$5.34 |
About 90% of Vion's Class A warrants were exercised for $4.63 each, for a total of $4.71M; holders received a total of 1.07M shares of common stock and 1.07M shares of Class B warrants; also, holders of the company's 0.23M unit purchase options exchanged 0.12M of these options, generating $0.62M; the options were exchanged for 0.12M shares of stock, 0.13M Class A warrants (immediately exchanged for 0.13M shares and 0.13M Class B warrants) and 0.13M Class B warrants (3/14) |
Viragen Inc.(OTC BB: VRGN) |
Shelf registration |
-- |
-- |
Viragen is seeking to raise $60M this year via equity equity financing through Ladenburg Thalmann & Co. (3/14) |
NOTES: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Non-U.S. currencies converted at the exchange rate on the date of the announcement. | ||||
@ Dates refer to the date of the press release. | ||||
ASX = Australian Stock Exchange | ||||
LSE = London Stock Exchange | ||||
TSE = Toronto Stock Exchange | ||||
VSE = Vancouver Stock Exchange |
||||
OTC BB = Over The Counter Bulletin Board |